Liver steatosis associated with chronic hepatitis C

Romanian Journal of Morphology and Embryology

Volumn 55, Issue 2, 2014, Pages 351-356

  Irimia, Eugenia ^a   Mogoantǎ, Laurenţiu ^a   Predescu, Ion Octavian ^a   Efrem, Ion Cristian ^a   Stǎnescu, Casiana ^b   Streba, LetiţIa Adela Maria ^a   Georgescu, Anca Meda ^c  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b VASILE GOLDIS WESTERN UNIVERSITY OF ARAD   (Romania)

^c UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chronic liver disease; Hepatic fibrosis; Hepatic steatosis; Hepatitis c virus; Liver inflammation

Indexed keywords

ADULT; AGED; COMPLICATION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84903157876     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Crabb DW, Galli A, Fischer M, You M, Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha, Alcohol, 2004, 34(1):35-38.
2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 2005, 129(1):113-121.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 2004, 40(6):1387-1395.
4. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY, Prevalence of and risk factors for fatty liver in a general population of Shanghai, China, J Hepatol, 2005, 43(3):508-514.
5. Hooper AJ, Adams LA, Burnett JR, Genetic determinants of hepatic steatosis in man, J Lipid Res, 2011, 52(4):593-617.
6. Ozturk Y, Soylu OB, Fatty liver in childhood, World J Hepatol, 2014, 6(1):33-40.
7. Preiss D, Sattar N, Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations, Clin Sci (Lond), 2008, 115(5):141-150.
8. Roden M, Mechanisms of disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance, Nat Clin Pract Endocrinol Metab, 2006, 2(6):335-348.
9. Lewis JR, Mohanty SR, Nonalcoholic fatty liver disease: a review and update, Dig Dis Sci, 2010, 55(3):560-578.
10. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI, The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome, Proc Natl Acad Sci USA, 2007, 104(31): 12587-12594.
11. Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K, Hwang JH, Giani G, Hoffmann B, Pacini G, Gastaldelli A, Roden M, Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance, PLoS One, 2014, 9(4):e94059.
12. Reddy JK, Rao MS, Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation, Am J Physiol Gastrointest Liver Physiol, 2006, 290(5):G852-G858.
13. Cholet F, Nousbaum JB, Richecoeur M, Oger E, Cauvin JM, Lagarde N, Robaszkiewicz M, Gouérou H, Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients, Gastroenterol Clin Biol, 2004, 28(3):272-278.
14. Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E, Mondelli MU, Colombo M, Pinzello G, Craxì A, Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C, Hepatology, 2006, 43(1):64-71.
15. Cohen JC, Horton JD, Hobbs HH, Human fatty liver disease: old questions and new insights, Science, 2011, 332(6037): 1519-1523.
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G, Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity, Hepatology, 2001, 33(6):1358-1364.
17. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F, Steatosis in chronic hepatitis C: why does it really matter? Gut, 2006, 55(1):123-130.
18. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G, Hepatitis C and steatosis: a reappraisal, J Viral Hepat, 2006, 13(2):73-80.
19. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL, Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol, Hepatology, 2002, 36(3):729-736.
20. Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D, Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies, Gut, 2003, 52(2):288-292.
21. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J, Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C, Hepatology, 2003, 38(1):75-85.
22. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG, The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients, J Hepatol, 2004, 40(3):484-490.
23. Clark JM, Brancati FL, Diehl AM, Nonalcoholic fatty liver disease, Gastroenterology, 2002, 122(6):1649-1657.
24. Kumar D, Farrell GC, Fung C, George J, Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response, Hepatology, 2002, 36(5):1266-1272.
25. Wu JY, Shu Chen L, Gui Qiang W, Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C, Liver Int, 2006, 26(2): 166-172.
26. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R, Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C, J Hepatol, 2001, 34(3):428-434.
27. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P, Hepatitis C virusassociated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis, Am J Gastroenterol, 2003, 98(5):1150-1154.
28. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, Rossi C, Mangia A, Negro F, An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation, J Hepatol, 2005, 42(5):744-751.
29. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C, Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis, FASEB J, 2002, 16(2):185-194.
30. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS, Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome, Am J Gastroenterol, 2003, 98(9):2064-2071.
31. AlQaraawi AM, Sanai FM, Al-Husseini H, Albenmousa A, AlSheikh A, Ahmed LR, Hersi A, Al-Otaibi MM, Syed M, Ali SM, Al-hamoudi W, Alswat KA, Abdo AA, Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C, Dig Dis Sci, 2011, 56(4):1222-1228.
32. Moucari R1, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P, Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis, Gastroenterology, 2008, 134(2):416-423.
33. Browning JD, Horton JD, Molecular mediators of hepatic steatosis and liver injury, J Clin Invest, 2004, 114(2):147-152.
34. Peverill W, Powell LW, Skoien R, Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation, Int J Mol Sci, 2014, 15(5):8591-8638.
35. Kinnman N, Housset C, Peribiliary myofibroblasts in biliary type liver fibrosis, Front Biosci, 2002, 7:d496-d503.
36. Wallace K, Burt AD, Wright MC, Liver fibrosis, Biochem J, 2008, 411(1):1-18.
37. Ionescu AG, Streba LA, Vere CC, Ciurea ME, Streba CT, Ionescu M, Comǎnescu M, Irimia E, Rogoveanu O, Histopathological and immunohistochemical study of hepatic stellate cells in patients with viral C chronic liver disease, Rom J Morphol Embryol, 2013, 54(4):983-991.
38. Svegliati-Baroni G, Ridolfi F, Di Sario A, Saccomanno S, Bendia E, Benedetti A, Greenwel P, Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells, Hepatology, 2001, 33(5):1130-1140.
39. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, Torok NJ, Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo, Hepatology, 2006, 43(3):435-443.
40. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P, High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis, Hepatology, 2001, 34(4 Pt 1):738-744.